Canlyniadau Chwilio

Review: Targeting the Hedgehog pathway in cancer gan Sachin Gupta, Naoko Takebe, Patricia LoRusso

Cael y testun llawn Cael y testun llawn

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects gan Richard Graham, Cornelis E. C. A. Hop, Marie T. Borin, Bert L. Lum, Dawn Colburn, Ilsung Chang, Young G. Shin, Vikram Malhi, Jennifer A. Low, Mark J. Dresser

Cael y testun llawn

Non-Canonical Hh Signaling in Cancer—Current Understanding and Future Directions gan Dongsheng Gu, Jingwu Xie

Cael y testun llawn

GLI2 is a novel therapeutic target for metastasis of osteosarcoma gan Hiroko Nagao‐Kitamoto, Masahito Nagata, Satoshi Nagano, Sho Kitamoto, Yasuhiro Ishidou, Takuya Yamamoto, Shunsuke Nakamura, Arisa Tsuru, Masahiko Abematsu, Yusuke Fujimoto, Masahiro Yokouchi, Shinichi Kitajima, Takako Yoshioka, Shingo Maeda, Suguru Yonezawa, Setsuro Komiya, Takao Setoguchi

Cael y testun llawn Cael y testun llawn

Midline carcinoma with t(15;19) and BRD4-NUTfusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy gan Jens Engleson, Maria Soller, Ioannis Panagopoulos, Anna Dahlén, Michael Dictor, Mats Jerkeman

Cael y testun llawn Cael y testun llawn

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma gan Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard Mackey, B. Lum, Walter C. Darbonne, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low

Cael y testun llawn Cael y testun llawn

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma gan Hayley J. Sharpe, Grégoire Pau, Gerrit J.P. Dijkgraaf, Nicole Basset‐Séguin, Zora Modrušan, Thomas Januario, Vickie Tsui, Alison B. Durham, Andrzej A. Dlugosz, Peter M. Haverty, Richard Bourgon, Jean Y. Tang, Kavita Y. Sarin, Luc Dirix, David C. Fisher, Charles M. Rudin, Howard Sofen, Michael R. Migden, Robert L. Yauch, Frédéric J. de Sauvage

Cael y testun llawn

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma gan Erqi L. Pollom, Timothy T. Bui, Anne Lynn S. Chang, A. Dimitrios Colevas, Wendy Hara

Cael y testun llawn Cael y testun llawn

Definition of Critical Periods for Hedgehog Pathway Antagonist-Induced Holoprosencephaly, Cleft Lip, and Cleft Palate gan Galen W. Heyne, Cal G. Melberg, Padydeh Doroodchi, Kia F. Parins, Henry W. Kietzman, Joshua L. Everson, Lydia J. Ansen-Wilson, Robert J. Lipinski

Cael y testun llawn Cael y testun llawn

Novel Hedgehog pathway targets against basal cell carcinoma gan Jean Y. Tang, Po‐Wah So, E EPSTEINJR

Cael y testun llawn

Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes gan Monica Dentice, Cristina Luongo, Stephen A. Huang, Raffaele Ambrosio, Antonia Elefante, Delphine Mirebeau‐Prunier, Ann Marie Zavacki, Gianfranco Fenzi, Marina Grachtchouk, Mark E. Hutchin, Andrzej A. Dlugosz, Antônio C. Bianco, Caterina Missero, P. Reed Larsen, Domenico Salvatore

Cael y testun llawn

Small‐Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics gan Stefan Peukert, Karen Miller‐Moslin

Cael y testun llawn Cael y testun llawn

Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma gan Anne Lynn S. Chang, Anthony E. Oro

Cael y testun llawn

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma gan Sabrina Pricl, Barbara Cortelazzi, Valentina Dal Col, Domenico Marson, Erik Laurini, Maurizio Fermeglia, Lisa Licitra, Silvana Pilotti, Paolo Bossi, Federica Perrone

Cael y testun llawn

Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma gan Edward Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Khan, John Blau, Ronald A. Craig, Ulysses J. Balis, Mark M. Zalupski, Diane M. Simeone

Cael y testun llawn Cael y testun llawn

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds gan Hyekyung Yang, Wei‐na Cong, Jeong Seon Yoon, Josephine M. Egan

Cael y testun llawn Cael y testun llawn

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma gan Howard Sofen, Kenneth G. Gross, Leonard H. Goldberg, Harry H. Sharata, Tiffani K. Hamilton, Barbara M. Egbert, Benjamin Lyons, Jeannie Hou, Ivor Caro

Cael y testun llawn

Vismodegib for Periocular and Orbital Basal Cell Carcinoma gan Harmeet Gill, Eve E. Moscato, Anne Lynn S. Chang, Seaver L. Soon, Rona Z. Silkiss

Cael y testun llawn Cael y testun llawn

The dawn of hedgehog inhibitors: Vismodegib gan Sandhiya Selvarajan, George Melvin, Srinivasamurthy Suresh Kumar, Steven Aibor Dkhar

Cael y testun llawn

Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome gan Jean Y. Tang, Julian Mackay‐Wiggan, Michelle Aszterbaum, Robert L. Yauch, Joselyn Lindgren, Kris S. Chang, Carol Coppola, Anita M. Chanana, Jackleen Marji, David R. Bickers, Ervin H. Epstein

Cael y testun llawn Cael y testun llawn